Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | BLM | P54132 | 4/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876644 | 1.00 | EGFR (0.67) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL13928220 | 0.80 | EGFR (0.64) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| Tyrphostin 23 SCHEMBL29360636 | 0.80 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| Tyrphostin 23 SCHEMBL241922 | 0.80 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL13060220 | 0.80 | EGFR (0.77) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| Tyrphostin 47 SCHEMBL1704818 | 0.79 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| Tyrphostin 47 SCHEMBL5802735 | 0.79 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6285299 | 0.79 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| Tyrphostin 47 SCHEMBL5802738 | 0.79 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL7908162 | 0.79 | EGFR (0.71) | EGFRKDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0403238-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1990-12-19 | — | — | EP | claimed |
| EP-4340807-A1 | HAIR COLOR COMPOSITIONS FOR MITIGATING COLOR LOSS | Lubrizol Advanced Materials, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3773458-A1 | HAIR MODIFICATION COMPOSITION AND METHOD THEREFOR | Lubrizol Advanced Materials, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10905646-B2 | Thermoplastic polyurethane film for delivery of active agents to skin surfaces | LUBRIZOL ADVANCED MATERIALS, INC. | 2021-02-02 | — | — | US | disclosed |
| US-10758490-B2 | Nanocapsules containing microemulsions | LIPOTEC, S.A. (ES) | 2020-09-01 | — | — | US | disclosed |
| EP-1515712-B1 | USE OF TAURINE FOR THE TREATMENT OF ALOPECIA | OREAL (FR) | 2019-12-25 | — | — | EP | disclosed |
| WO-2019200027-A1 | HAIR MODIFICATION COMPOSITION AND METHOD THEREFOR | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-2618926-B1 | NANOCAPSULES CONTAINING MICROEMULSIONS | LIPOTEC SA (ES) | 2019-05-08 | — | — | EP | disclosed |
| US-20180311358-A1 | THERMOFORMABLE DUAL NETWORK HYDROGEL COMPOSITIONS | LUBRIZOL ADVANCED MATERIALS, INC. | 2018-11-01 | — | — | US | disclosed |
| EP-3371238-A1 | THERMOFORMABLE DUAL NETWORK HYDROGEL COMPOSITIONS | Lubrizol Advanced Materials, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| US-5328914-A | Use of pyrimidine 3-oxide derivatives for slowing down hair loss and topical compositions used | L'OREAL (FR) | 1994-07-12 | — | — | US | disclosed |
| EP-0580409-A2 | Cosmetic composition containing DOPA derivatives | UNILEVER PLC (GB) | 1994-01-26 | — | — | EP | disclosed |
| EP-0572167-A1 | Cosmestic composition | UNILEVER PLC (GB) | 1993-12-01 | — | — | EP | disclosed |
| EP-0571198-A1 | Cosmetic composition containing hair-growth promoter | UNILEVER PLC (GB) | 1993-11-24 | — | — | EP | disclosed |
| EP-0519819-A1 | Composition for use to reduce hair loss and to induce and stimulate its growth, containing derivatives of 2,4,6-triaminopyrimidin-N-oxide and the new derivatives of 2,4,6-triaminopyrimidin-N-oxide | L'OREAL (FR) | 1992-12-23 | — | — | EP | disclosed |
| EP-0517371-A2 | Hair growth composition containing citric acid esters | UNILEVER PLC (GB) | 1992-12-09 | — | — | EP | disclosed |
| US-5124354-A | Hair growth | CHESEBROUGH POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0490581-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1992-06-17 | — | — | EP | disclosed |
| WO-1992001437-A1 | USE OF PYRIMIDINE 3-OXYDE DERIVATIVES TO SLOW DOWN HAIR FALL AND TOPICAL COMPOSITIONS IMPLEMENTED | L'OREAL (FR) | 1992-02-06 | — | — | WO | disclosed |
| EP-0403238-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905646-B2 | Thermoplastic polyurethane film for delivery of active agents to skin surfaces | DNER, CUTA, PUF60 | EGFR 128/4885KDM4E 577/4885MEN1 2856/4885 |
| US-20180311358-A1 | THERMOFORMABLE DUAL NETWORK HYDROGEL COMPOSITIONS | HSF1, DUOX2, HSPA2 | EGFR 1509/4885KDM4E 4554/4885MEN1 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.